1. Wang, M. Clinical trials and drug approvals continue to accelerate in China. Lancet Oncol. 18, 855 (2017).
2. Zhou, Q., Chen, X. Y., Yang, Z. M. & Wu, Y. L. The changing landscape of clinical trial and approval processes in China. Nat. Rev. Clin. Oncol. 14, 577–583 (2017).
3. National Medical Products Administration. National Medical Products Administration Approves Zanubrutinib http://www.nmpa.gov.cn/WS04/CL2056/377969.html (2020).
4. U.S. Food and Drug Administration. Drug Approval Package: BRUKINSA https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000TOC.cfm (2019).
5. Nasdaq Investors. BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma http://ir.beigene.com/news-releases/news-release-details/beigene-announces-approval-brukinsatm-zanubrutinib-china (2020).